EU H2020 Project "NEOFIBRIN (Advanced material for the regeneration of oral mucosa injuries)": description, partecipants, costs and EC-fundings

#	Pagina
attuale pagina	/open-h2020/projects/208022/index.html
-1	/open-fp7/projects/92310/index.html
-2	/open-fp7/projects/88068/index.html
-3	/open-fp7/projects/98823/index.html
-4	/open-h2020/projects/208527/index.html
-5	/open-fp7/projects/104049/index.html
-6	/open-fp7/projects/105505/index.html
-7	/open-fp7/projects/105214/index.html
-8	/open-h2020/projects/200747/index.html
-9	/open-fp7/projects/108577/index.html
-10	/open-h2020/per-topic/lambda/list/index.html

NEOFIBRIN project word cloud

Explore the words cloud of the NEOFIBRIN project. It provides you a very rough idea of what is the project "NEOFIBRIN" about.

marketed grafts supportive larger instrument extracellular rights plan medicine mucosa suturing invasion mark oral efficiency techniques consistency maturation structural tissues mechanical wound histocell capacity completion engineering successful restoring autologous functional proliferation industrialization scaffolds damage mucosal seaweed manufacturing proteins phases facility neofibrin artificial fibrin obtain human accomplishment market specialized generation localized scaffold matrix cell regeneration sme hr018 provides feasibility company sem maintaining treatment tissue epithelium biomaterial migration masticatory combining facilitates allogenic alternative significantly temporary progressive treat gives surgical clinical accelerating material yield dentistry seek materials injuries exclusive polysaccharide licensing ce tridimensional innovative healing medical adapt agarose business regenerative natural

Project "NEOFIBRIN" data sheet

The following table provides information about the project.

Coordinator	HISTOCELL SL Organization address address: PARQUE TECNOLOGICO DE BIZKAIA EDIFICIO 801 PISO 2 city: DERIO BIZKAIA postcode: 48160 website: www.histocell.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Spain [ES]
Project website	http://www.histocell.com/index.php/en/r-d/current-projects/138-neofibrin
Total cost	71˙429 €
EC max contribution	50˙000 € (70%)
Programme	1. H2020-EU.2.1.5. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced manufacturing and processing) 2. H2020-EU.2.1.3. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced materials) 3. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument) 4. H2020-EU.2.1.2. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies)
Code Call	H2020-SMEINST-1-2016-2017
Funding Scheme	SME-1
Starting year	2017
Duration (year-month-day)	from 2017-02-01 to 2017-07-31

#	participants	country	role	EC contrib. [€]
1	HISTOCELL SL	ES (DERIO BIZKAIA)	coordinator	50˙000.00

HISTOCELL SL

ES (DERIO BIZKAIA)

coordinator

50˙000.00

Project objective

The main objective of NEOFIBRIN is to undertake a technical, industrialization and market feasibility study on an innovative regenerative medicine treatment for masticatory oral mucosa injuries based on a new advanced material, HR018-Neofibrin. The use of this material to develop a tridimensional natural scaffold for restoring masticatory oral mucosa functional activity is expected to significantly increase treatment efficiency over currently marketed products and to provide an alternative to allogenic and autologous grafts to treat localized mucosal damage. The application of Tissue Engineering techniques in clinical dentistry has several well-known problems, key among them the generation of a supportive biomaterial with regenerative capacity without the loss of consistency. Our novel biomaterial HR018-Neofibrin was developed combining natural materials and an exclusive design to promote the progressive formation and maturation of new epithelium while maintaining structural properties. Fibrin, one of the proteins involved in wound healing, provides a temporary extracellular matrix that facilitates cell migration, invasion and proliferation. Agarose, a polysaccharide from seaweed, gives the mechanical properties that enable surgical suturing and open healing. Histocell, a SME specialized in human regenerative medicine, has obtained licensing rights to the production of fibrin-agarose based artificial tissues and scaffolds for regeneration of tissues and oral mucosa. Successful completion of Phase 1 of NEOFIBRIN will yield a robust business plan for a much larger project that will seek funding under Phase 2 of the SEM Instrument, when the company will adapt a new facility for advanced manufacturing of innovative medical devices for the production of the new biomaterial HR018-Neofibrin and undertake clinical studies to obtain CE Mark for the product. Successful accomplishment of Phases 1 and 2 will be essential for accelerating the growth of the SME Histocell.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NEOFIBRIN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NEOFIBRIN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.5.;H2020-EU.2.1.3.;H2020-EU.2.3.1.;H2020-EU.2.1.2.)